Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin- releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing

Women with polycystic ovary syndrome (PCOS: hyperandrogenism and oligomenorrhea) have been shown to have exaggerated ovarian 17-hydroxyprogesterone (17-OHP) responses after GnRH agonist stimulation, suggestive of disordered ovarian cytochrome P450c17 alpha activity. However, most hyperandrogenic wom...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 81; no. 11; pp. 4103 - 4107
Main Author Ibanez, L.
Format Journal Article
LanguageEnglish
Published Bethesda, MD Endocrine Society 01.11.1996
Subjects
Online AccessGet full text
ISSN0021-972X
DOI10.1210/jc.81.11.4103

Cover

Abstract Women with polycystic ovary syndrome (PCOS: hyperandrogenism and oligomenorrhea) have been shown to have exaggerated ovarian 17-hydroxyprogesterone (17-OHP) responses after GnRH agonist stimulation, suggestive of disordered ovarian cytochrome P450c17 alpha activity. However, most hyperandrogenic women also have an exaggerated LH response to both native GnRH and GnRH agonists. To assess whether the known LH hyperresponsiveness in PCOS patients mediates their exaggerated 17-OHP response to GnRH agonist challenge or whether the 17-OHP response can be duplicated by direct stimulation of the ovary with a fixed amount of hCG, 25 PCOS women [age, 20.6 +/- 1.1 yr; body mass index (BMI), 24.9 +/- 1.3 kg/m2] and 5 controls (age, 29.4 +/- 2.3 yr; BMI, 29.2 +/- 3.0) underwent both GnRH agonist (leuprolide acetate) and hCG testing. In addition, 23 normal women (age, 26.5 +/- 1.5 yr; BMI, 27.2 +/- 1.7 kg/m2) underwent hCG testing, and 21 other normal women (age, 19.3 +/- 0.5 yr; BMI, 23.0 +/- 0.8 kg/m2) underwent leuprolide acetate challenge. Blood was sampled before and 24 h after (the previously determined time of the peak response) leuprolide acetate (500 micrograms, sc) and hCG (5000 IU, im) stimulation tests. The tests were administered during the early follicular phase in women who were ovulatory and in randomized order in the subjects receiving both stimuli. Peak serum 17-OHP levels did not differ between leuprolide acetate or hCG stimulation in PCOS patients or controls when measured at 24 h (324.9 +/- 41.9 vs. 360.4 +/- 54.0 in PCOS; 183.2 +/- 19.6 vs. 141.2 +/- 11 ng/dL in controls). Peak 17-OHP levels after hCG challenge and GnRH agonist stimulation were highly correlated (r = 0.82; P < 0.001) in the subjects receiving both stimuli. Although leuprolide acetate elicited a higher estradiol (E2) response than hCG in all subjects, serum E2 levels increased significantly after hCG treatment in both patients and controls (P < 0.001 and P < 0.0001). The small, but significant, increase in serum E2 after hCG stimulation suggests that a rigid two-cell model of ovarian steroidogenesis may be an oversimplification of in vivo physiology. Our results suggest that exaggerated 17-OHP responses to GnRH agonist stimulation in hyperandrogenic women are not mediated by the known hyperresponsiveness of LH in these patients, but are due to increased ovarian androgen sensitivity to LH stimulation.
AbstractList Women with polycystic ovary syndrome (PCOS: hyperandrogenism and oligomenorrhea) have been shown to have exaggerated ovarian 17-hydroxyprogesterone (17-OHP) responses after GnRH agonist stimulation, suggestive of disordered ovarian cytochrome P450c17 alpha activity. However, most hyperandrogenic women also have an exaggerated LH response to both native GnRH and GnRH agonists. To assess whether the known LH hyperresponsiveness in PCOS patients mediates their exaggerated 17-OHP response to GnRH agonist challenge or whether the 17-OHP response can be duplicated by direct stimulation of the ovary with a fixed amount of hCG, 25 PCOS women [age, 20.6 +/- 1.1 yr; body mass index (BMI), 24.9 +/- 1.3 kg/m2] and 5 controls (age, 29.4 +/- 2.3 yr; BMI, 29.2 +/- 3.0) underwent both GnRH agonist (leuprolide acetate) and hCG testing. In addition, 23 normal women (age, 26.5 +/- 1.5 yr; BMI, 27.2 +/- 1.7 kg/m2) underwent hCG testing, and 21 other normal women (age, 19.3 +/- 0.5 yr; BMI, 23.0 +/- 0.8 kg/m2) underwent leuprolide acetate challenge. Blood was sampled before and 24 h after (the previously determined time of the peak response) leuprolide acetate (500 micrograms, sc) and hCG (5000 IU, im) stimulation tests. The tests were administered during the early follicular phase in women who were ovulatory and in randomized order in the subjects receiving both stimuli. Peak serum 17-OHP levels did not differ between leuprolide acetate or hCG stimulation in PCOS patients or controls when measured at 24 h (324.9 +/- 41.9 vs. 360.4 +/- 54.0 in PCOS; 183.2 +/- 19.6 vs. 141.2 +/- 11 ng/dL in controls). Peak 17-OHP levels after hCG challenge and GnRH agonist stimulation were highly correlated (r = 0.82; P < 0.001) in the subjects receiving both stimuli. Although leuprolide acetate elicited a higher estradiol (E2) response than hCG in all subjects, serum E2 levels increased significantly after hCG treatment in both patients and controls (P < 0.001 and P < 0.0001). The small, but significant, increase in serum E2 after hCG stimulation suggests that a rigid two-cell model of ovarian steroidogenesis may be an oversimplification of in vivo physiology. Our results suggest that exaggerated 17-OHP responses to GnRH agonist stimulation in hyperandrogenic women are not mediated by the known hyperresponsiveness of LH in these patients, but are due to increased ovarian androgen sensitivity to LH stimulation.
Author Ibanez, L.
Author_xml – sequence: 1
  givenname: L.
  surname: Ibanez
  fullname: Ibanez, L.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2479667$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/8923867$$D View this record in MEDLINE/PubMed
BookMark eNptUk1v1DAQDVJRaQtHjpXmwAEOWWwnmw9uqCotUqVKCCRu0cSebLxK7Mj2LqS_Hme7VBXiYkue9968N57z5MRYQ0nylrMVF5x93MpVxVecr3LOspPkjDHB07oUP18l595vGeN5vs5Ok9OqFllVlGcvLu_36DQa4GXaz8rZ3_Pk7IZ8IBe1oZ8nco78ZI3XezLkPQQLG2tQ2eDspE0KjgZCr80GeuvGhfb-xny7_QAYcdoHkD0OA5kNgTbwy44UTx16mOwwy9kHLcFGHzP42UQPY8R5MDbASEpjIAXtDMMukDb64Xmfgz1P0lHQ1nwC2mtFRhJ0UQUWE08e0Cjod2OMKiM7omPT5zEg2hh3Ay5CEOIAYp_XycsOB09vjvdF8uPL9fer2_Tu_ubr1ee7VIqqCGlOissy40VXSJFlmWRrIQslFMqCVSXGR06izRRf5wVh3daIuWQKu7xlKLrsIrl81J12bYzcTE6PcRzN8Zti_d2xjl7i0Dk0UvsnmMjLujjAskeYdNZ7R10jdTgECg710HDWLGvSbGVT8YbzZlmTyEr_Yf3V_T_-Dwcjy2w
CODEN JCEMAZ
CitedBy_id crossref_primary_10_1046_j_1528_1157_2001_042suppl_3060_x
crossref_primary_10_1093_humrep_16_12_2546
crossref_primary_10_1016_S1472_6483_10_62129_3
crossref_primary_10_1016_S0303_7207_98_00178_6
crossref_primary_10_1016_j_mcna_2008_04_008
crossref_primary_10_1016_S1043_2760_98_00014_9
crossref_primary_10_1016_S1043_2760_98_00018_6
crossref_primary_10_1016_S1083_3188_98_70115_9
crossref_primary_10_1016_j_ecl_2011_08_003
crossref_primary_10_1067_mjd_2001_117430
crossref_primary_10_1016_S1083_3188_98_70132_9
crossref_primary_10_1016_S0889_8529_05_70070_0
crossref_primary_10_1016_j_ejogrb_2004_06_024
crossref_primary_10_1097_00019616_200207000_00011
crossref_primary_10_1016_S0960_0760_99_00044_8
crossref_primary_10_1111_j_1528_1167_2010_02897_x
crossref_primary_10_1111_cen_12690
ContentType Journal Article
Copyright 1997 INIST-CNRS
Copyright_xml – notice: 1997 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1210/jc.81.11.4103
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EndPage 4107
ExternalDocumentID 8923867
2479667
10_1210_jc_81_11_4103
Genre Research Support, U.S. Gov't, P.H.S
Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: NCRR NIH HHS
  grantid: M01-RR-01066
– fundername: NICHD NIH HHS
  grantid: U54-HD-29164
– fundername: NICHD NIH HHS
  grantid: P30-HD-28138
GroupedDBID ---
-~X
.55
.GJ
0R~
18M
1TH
2WC
3O-
4.4
48X
53G
5GY
5YH
AABZA
AACZT
AAIMJ
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAVAP
AAWTL
AAYXX
ABBLC
ABDFA
ABDPE
ABEJV
ABGNP
ABJNI
ABLJU
ABMNT
ABNHQ
ABOCM
ABPPZ
ABPQP
ABPTD
ABQNK
ABVGC
ABWST
ABXVV
ABXZS
ACGFO
ACGFS
ACPRK
ACYHN
ADGKP
ADGZP
ADHKW
ADNBA
ADQBN
ADRTK
ADVEK
AEHZK
AELWJ
AEMDU
AEMQT
AENEX
AENZO
AEOTA
AETBJ
AEWNT
AFFNX
AFFZL
AFGWE
AFOFC
AFRAH
AFXAL
AFYAG
AGINJ
AGQXC
AGUTN
AHMBA
AHMMS
AI.
AJEEA
ALMA_UNASSIGNED_HOLDINGS
ALXQX
APIBT
ARIXL
ATGXG
BAYMD
BCRHZ
BEYMZ
BSWAC
BTRTY
CDBKE
CITATION
CS3
DAKXR
EBS
EJD
ENERS
F5P
FECEO
FHSFR
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
J5H
KBUDW
KOP
KSI
KSN
L7B
MHKGH
MJL
N4W
N9A
NLBLG
NOMLY
NOYVH
NU-
NVLIB
O9-
OAUYM
ODMLO
OJZSN
OK1
OPAEJ
OVD
P2P
REU
ROX
ROZ
TEORI
TJX
TLC
TMA
TWZ
VH1
VVN
X52
X7M
YBU
YOC
ZGI
ZXP
ZY1
~02
.XZ
08P
29K
34G
354
39C
5RS
7X7
88E
8F7
8FI
8FJ
AAJQQ
AAKAS
AAPGJ
AAUQX
AAWDT
AAYJJ
ABPMR
ABUWG
ACFRR
ACUTJ
ACVCV
ACZBC
ADBBV
ADMTO
ADZCM
AERZD
AFCHL
AFFQV
AFKRA
AGKRT
AGMDO
AGORE
AHGBF
AJBYB
AJDVS
APJGH
AQDSO
AQKUS
ASPBG
AVNTJ
AVWKF
AZFZN
BAWUL
BENPR
BPHCQ
BVXVI
C45
CCPQU
D-I
DIK
E3Z
EIHJH
EMOBN
FEDTE
FYUFA
HMCUK
HVGLF
HZ~
H~9
IAO
IHR
INH
IQODW
ITC
M1P
M5~
MBLQV
OBFPC
OBH
OCB
OFXIZ
OGEVE
OHH
OVIDX
P6G
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
TR2
UKHRP
W8F
WHG
WOQ
YFH
YHG
YSK
~H1
CGR
CUY
CVF
ECM
EIF
NPM
ID FETCH-LOGICAL-c286t-4ed1c7316f6c2333c052c6d2dac6087ac231e2b3d1546ea9b9aa4c0daf4b0a2f3
ISSN 0021-972X
IngestDate Sun May 25 02:33:38 EDT 2025
Mon Jul 21 09:17:24 EDT 2025
Wed Oct 01 00:49:44 EDT 2025
Thu Apr 24 23:08:49 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords Human
Agonist
Peptide hormone
Gonadotropin RH
Female sterility
Gonadotropin
Polycystic ovary
Glycoprotein hormone
HCG
Placental hormone
Female genital diseases
Hypothalamic hormone
Ovarian diseases
Chemotherapy
Treatment
Cyst
Female
Benign neoplasm
Biological effect
Hormonal investigation
Hormone releasing factor
Comparative study
Hydroxyprogesterone
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c286t-4ed1c7316f6c2333c052c6d2dac6087ac231e2b3d1546ea9b9aa4c0daf4b0a2f3
PMID 8923867
PageCount 5
ParticipantIDs pubmed_primary_8923867
pascalfrancis_primary_2479667
crossref_citationtrail_10_1210_jc_81_11_4103
crossref_primary_10_1210_jc_81_11_4103
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate 1996-11-01
PublicationDateYYYYMMDD 1996-11-01
PublicationDate_xml – month: 11
  year: 1996
  text: 1996-11-01
  day: 01
PublicationDecade 1990
PublicationPlace Bethesda, MD
PublicationPlace_xml – name: Bethesda, MD
– name: United States
PublicationTitle The journal of clinical endocrinology and metabolism
PublicationTitleAlternate J Clin Endocrinol Metab
PublicationYear 1996
Publisher Endocrine Society
Publisher_xml – name: Endocrine Society
SSID ssj0014453
Score 1.8072577
Snippet Women with polycystic ovary syndrome (PCOS: hyperandrogenism and oligomenorrhea) have been shown to have exaggerated ovarian 17-hydroxyprogesterone (17-OHP)...
SourceID pubmed
pascalfrancis
crossref
SourceType Index Database
Enrichment Source
StartPage 4103
SubjectTerms 17-alpha-Hydroxyprogesterone - blood
Adolescent
Adult
Biological and medical sciences
Case-Control Studies
Chorionic Gonadotropin - pharmacology
Estradiol - blood
Female
Female genital diseases
Gonadotropin-Releasing Hormone - agonists
Gynecology. Andrology. Obstetrics
Humans
Leuprolide - pharmacology
Luteinizing Hormone - secretion
Medical sciences
Non tumoral diseases
Ovary - drug effects
Ovary - secretion
Polycystic Ovary Syndrome - physiopathology
Title Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin- releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing
URI https://www.ncbi.nlm.nih.gov/pubmed/8923867
Volume 81
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  issn: 0021-972X
  databaseCode: GX1
  dateStart: 19960101
  customDbUrl:
  isFulltext: true
  dateEnd: 20241003
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  omitProxy: true
  ssIdentifier: ssj0014453
  providerName: Geneva Foundation for Medical Education and Research
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3ra9swEMC1toMxKGOvsm7LuA9jbHQO8SOyvG9jbA1jDxgt9FuQZLlJSe3QuIX0r9-dLCtOl0G3LyY4siVbP0t3xz0Ye50Vw0yqRAVcxCZIhBSB0DIMCpWnMtQqjKXN9vmDj46TryfDk63t3Y7X0mWt-vp6Y1zJ_8wqnsN5pSjZf5hZf1M8gb9xfvGIM4zHW83xzyvUdG2JvWCyzMkhhdytbO6DCoXHCeqYVHvDOsG6RQ1FzVMUvlEXvaBQqcAWTZHWYDBB8bVqZM7D8teI7AUS2yIHFB7clFwh84hN2tAYcOfVbKmXlOr5oLoi_7s2AQLVSS-ruglMqRspF9-EmZbT625fdogLEl1bJxPjypw2gS80ED8KsvE3NQVxzb6Y2to93Yc5wIGcu3JkBzWlD3Hb8tnqk-hkyvBBoabMK1w8y1U6qnNT48cxa9Mr0qejZNkY27_1V5YS61wdektJG7kQBllqy7f71V-EXcrDzlqehIO4IxckrjzvH3sOKs205-i-CHED6q8u6-b2vrHnek9I0sHwBuMzPRYhqmNjunyb3Y1Szqkgx-GJ91hC1dclVXWP4VLGUhDWWu9rItbuXC7wVRZNmZYbypMVoo4esgdO-4GPDcqP2JYpH7N7351_x5M7PUc0bCYaNhANdQVrRIMnGhxl8JYwegeOI_A0w7QESzMQzbCiGSzN0NIM0wUgzdDSDGoJHZp9P-s0f4CWZSCWgQbhx4CUgWUZPMtrjwEdlsGx_JQdf_l89GkUuAImgY4Er4PE5KGm0nAF11Ecx3owjDTPo1xqPhCpxJOhiVScox7DjcxUJmWiB7ksEjWQURHvsZ0Sh_-MgdFCDVG3HBguEpkJkWSFMsMozxKlZCb32ft2zsfaZfenIjOz8UbC9tkb33zepLX5W8PeGkC-dZSkGefpPttrgPJ_CFQZBU-f37aHF-z-6mN9yXbqi0vTQ0G_Vq8s_r8BW4YT7g
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ovarian+17-hydroxyprogesterone+hyperresponsiveness+to+gonadotropin-+releasing+hormone+%28GnRH%29+agonist+challenge+in+women+with+polycystic+ovary+syndrome+is+not+mediated+by+luteinizing+hormone+hypersecretion%3A+evidence+from+GnRH+agonist+and+human+chorionic+gonadotropin+stimulation+testing&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Ibanez%2C+L.&rft.date=1996-11-01&rft.issn=0021-972X&rft.volume=81&rft.issue=11&rft.spage=4103&rft.epage=4107&rft_id=info:doi/10.1210%2Fjc.81.11.4103&rft.externalDBID=n%2Fa&rft.externalDocID=10_1210_jc_81_11_4103
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon